G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic

Cancer Research

Volumn 73, Issue 13, 2013, Pages 4134-4146

  Hsu, Danielle M ^a   Agarwal, Saurabh ^b,c   Benham, Ashley ^a,d   Coarfa, Cristian ^a,d   Trahan, Denae N ^b,c   Chen, Zaowen ^b,c   Stowers, Paris N ^b,c   Courtney, Amy N ^b,c   Lakoma, Anna ^a   Barbieri, Eveline ^b,c   Metelitsa, Leonid S ^b,c   Gunaratne, Preethi ^a,d   Kim, Eugene S ^a   Shohet, Jason M ^b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S CANCER CENTER   (United States)

^c Center for Cell and Gene Therapy   (United States)

^d University of Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; MICRORNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL ISOLATION; CELL RENEWAL; CELL SUBPOPULATION; CONTROLLED STUDY; CORRELATIONAL STUDY; CSF3R GENE; FEMALE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; MOUSE; MULTIPLE CYCLE TREATMENT; NEURAL CREST; NEUROBLASTOMA; NEUROECTODERM; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; MICRORNAS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROTO-ONCOGENE PROTEINS; RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR; SIDE-POPULATION CELLS; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880075721     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4056     Document Type: Article

References (50)

1. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362: 2202-11.
2. Laverdiere C, Liu Q, Yasui Y, Nathan PC, Gurney JG, Stovall M, et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009;101: 1131-40.
3. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009;138: 822-9.
4. Vermeulen L, de Sousa e Melo F, Richel DJ, Medema JP. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol 2012;13: e83-9.
5. Parashurama N, Lobo NA, Ito K, Mosley AR, Habte FG, Zabala M, et al. Remodeling of endogenous mammary epithelium by breast cancer stem cells. Stem Cells 2012;30: 2114-27.
6. Lin SP, Lee YT, Yang SH, Miller SA, Chiou SH, Hung MC, et al. Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis. Cancer Lett 2013;328: 226-34.
7. Hirschmann-Jax C, Foster AE, WulfGG, Nuchtern JG, JaxTW, Gobel U, et al. Adistinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004;101: 14228-33.
8. Hansford LM, McKee AE, Zhang L, George RE, Gerstle JT, Thorner PS, et al. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 2007;67: 11234-43.
9. Kamijo T. Role of stemness-related molecules in neuroblastoma. Pediatr Res 2012;71: 511-5.
10. Takenobu H, Shimozato O, Nakamura T, Ochiai H, Yamaguchi Y, Ohira M, et al. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 2011;30: 97-105.
11. Coulon A, Flahaut M, Muhlethaler-Mottet A, Meier R, Liberman J, Balmas-Bourloud K, et al. Functional sphere profiling reveals the complexity of neuroblastoma tumor-initiating cell model. Neoplasia 2011;13: 991-1004.
12. Jiang M, Stanke J, Lahti JM. The connections between neural crest development and neuroblastoma. Curr Top Dev Biol 2011;94: 77-127.
13. Jain AK, Allton K, Iacovino M, Mahen E, Milczarek RJ, Zwaka TP, et al. p53 regulates cell cycle and microRNAs to promote differentiation of human embryonic stem cells. PLoS Biol 2012;10: e1001268.
14. Hansford LM, Thomas WD, Keating JM, Burkhart CA, Peaston AE, Norris MD, et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci U S A 2004;101: 12664-9.
15. Nichane M, Ren X, Bellefroid EJ. Self-regulation of Stat3 activity coordinates cell-cycle progression and neural crest specification. EMBO J 2010;29: 55-67.
16. Ho PL, Kurtova A, Chan KS. Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat Rev Urol 2012;9: 583-94.
17. Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res 2011;71: 7226-37.
18. Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol 2012;39: 461-72.
19. Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009;27: 2383-92.
20. Kirsch F, Kruger C, Schneider A. The receptor for granulocyte-colony stimulating factor (G-CSF) is expressed in radial glia during development of the nervous system. BMC Dev Biol 2008;8: 32.
21. Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005;115: 2083-98.
22. Pitzer C, Klussmann S, Kruger C, Letellier E, Plaas C, Dittgen T, et al. The hematopoietic factor granulocyte-colony stimulating factor improves outcome in experimental spinal cord injury. J Neurochem 2010;113: 930-42.
23. Savarese TM, Mitchell K, McQuain C, Campbell CL, Guardiani R, Wuu J, et al. Coexpression of granulocyte colony stimulating factor and its receptor in primary ovarian carcinomas. Cancer Lett 2001;162: 105-15.
24. Chakraborty A, Guha S. Granulocyte colony-stimulating factor/granulocyte colony-stimulating factor receptor biological axis promotes survival and growth of bladder cancer cells. Urology 2007;69: 1210-5.
25. Hirai K, Kumakiri M, Fujieda S, Sunaga H, Lao LM, Imamura Y, et al. Expression of granulocyte colony-stimulating factor and its receptor in epithelial skin tumors. J Dermatol Sci 2001;25: 179-88.
26. Patterson DM, Shohet JM, Kim ES. Pre-clinical models of pediatric solid tumors (neuroblastoma) and their use in drug discovery. Curr Protoc Pharmacol 2011; Chapter 14: Unit 14.17.
27. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009;347: 70-8.
28. Bonnefoix T, Bonnefoix P, Verdiel P, Sotto JJ. Fitting limiting dilution experiments with generalized linear models results in a test of the single-hit Poisson assumption. J Immunol Methods 1996;194: 113-9.
29. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100: 672-9.
30. MeltonC, Blelloch R. MicroRNA regulation of embryonic stem cell selfrenewal and differentiation. Adv Exp Med Biol 2010;695: 105-17.
31. Anokye-Danso F, Trivedi CM, Juhr D, Gupta M, Cui Z, Tian Y, et al. Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell 2011;8: 376-88.
32. John N, Cinelli P, Wegner M, Sommer L. Transforming growth factor beta-mediated Sox10 suppression controls mesenchymal progenitor generation in neural crest stem cells. Stem Cells 2011;29: 689-99.
33. Crobu F, Latini V, Marongiu MF, Sogos V, Scintu F, Porcu S, et al. Differentiation of single cell derived human mesenchymal stem cells into cells with a neuronal phenotype: RNA and microRNA expression profile. Mol Biol Rep 2012;39: 3995-4007.
34. Skreka K, Schafferer S, Nat IR, Zywicki M, Salti A, Apostolova G, et al. Identification of differentially expressed non-coding RNAs in embryonic stem cell neural differentiation. Nucleic Acids Res 2012;40: 9980.
35. Beveridge NJ, Tooney PA, Carroll AP, Tran N, Cairns MJ. Downregulation of miR-17 family expression in response to retinoic acid induced neuronal differentiation. Cell Signal 2009;21: 1837-45.
36. Iwaniuk KM, Schira J, Weinhold S, Jung M, Adjaye J, Muller HW, et al. Network-like impact of MicroRNAs on neuronal lineage differentiation of unrestricted somatic stem cells from human cord blood. Stem Cells Dev 2011;20: 1383-94.
37. Mestdagh P, Bostrom AK, Impens F, Fredlund E, Van Peer G, De Antonellis P, et al. The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell 2010;40: 762-73.
38. Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, et al. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer 2008;122: 699-704.
39. Shohet JM, Ghosh R, Coarfa C, Ludwig A, Benham AL, Chen Z, et al. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Cancer Res 2011;71: 3841-51.
40. De Preter K, Mestdagh P, Vermeulen J, Zeka F, Naranjo A, Bray I, et al. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res 2011;17: 7684-92.
41. Chen Z, Lin Y, Barbieri E, Burlingame S, Hicks J, Ludwig A, et al. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Neoplasia 2009;11: 753-62.
42. Kim E, Shohet J. Targeted molecular therapy for neuroblastoma: the ARF/MDM2/p53 axis. J Natl Cancer Inst 2009;101: 1527-9.
43. Calao M, Sekyere EO, Cui HJ, Cheung BB, Thomas WD, Keating J, et al. Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation. Oncogene. 2012 Aug 20. [Epub ahead of print].
44. Neveu P, Kye MJ, Qi S, Buchholz DE, Clegg DO, Sahin M, et al. MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states. Cell Stem Cell 2010;7: 671-81.
45. Lu Y, Zhang K, Li C, Yao Y, Tao D, Liu Y, et al. Piwil2 suppresses p53 by inducing phosphorylation of signal transducer and activator of transcription 3 in tumor cells. PLoS ONE 2012;7: e30999.
46. Seo HS, Choi HS, Kim SR, Choi YK, Woo SM, Shin I, et al. Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFkappaB signaling in HER2-overexpressing breast cancer cells. Mol Cell Biochem 2012;366: 319-34.
47. Yang J, van Oosten AL, Theunissen TW, Guo G, Silva JC, Smith A. Stat3 activation is limiting for reprogramming to ground state pluripotency. Cell Stem Cell 2010;7: 319-28.
48. Prasad MS, Sauka-Spengler T, Labonne C. Induction of the neural crest state: control of stem cell attributes by gene regulatory, posttranscriptional and epigenetic interactions. Dev Biol 2012;366: 10-21.
49. Strobl-Mazzulla PH, Bronner ME. Epithelial to mesenchymal transition: new and old insights from the classical neural crest model. Semin Cancer Biol 2012;22: 411-6.
50. Dupin E,Sommer L. Neural crest progenitors and stem cells: from early development to adulthood. Dev Biol 2012;366: 83-95.